UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): November 13, 2026 |
Korsana Biosciences, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Massachusetts |
001-38787 |
83-1895370 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
203 Crescent Street Bldgs. #3/3A/4 Suite 503 |
|
Waltham, Massachusetts |
|
02453 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (781) 516-2325 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, no par value per share |
|
KRSA |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On November 13, 2026, Korsana Biosciences, Inc. (the “Company”) held a special meeting of shareholders (the “Special Meeting”) exclusively online via live webcast. As of October 7, 2026, the record date for the Special Meeting, 45,541,358 shares of the Company’s common stock were issued, outstanding and entitled to vote. A total of 40,022,552 shares were present at the Special Meeting in person or represented by proxy, constituting a quorum.
At the Special Meeting, the Company’s shareholders voted on the two proposals described below, each of which is described in greater detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 15, 2026 (the “Proxy Statement”). Proposal Nos. 1 and 2 together comprise the “Redomestication Proposal.” The final voting results for each proposal are set forth below.
Proposal No. 1. Shareholders approved, pursuant to the Massachusetts Business Corporation Act, the redomestication of the Company from a corporation organized under the laws of the Commonwealth of Massachusetts to an exempted company incorporated under the laws of the Cayman Islands by domestication pursuant to Section 9.20 of the Massachusetts Business Corporation Act, as set forth in the plan of domestication attached as Annex A to the Proxy Statement, and adopted the resolutions of the Board of Directors approving the redomestication, attached as Annex E to the Proxy Statement (the “Domestication Proposal”). The voting results were as follows:
|
|
|
|
|
|
|
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
36,182,762 |
|
3,839,724 |
|
67 |
|
— |
Proposal No. 2. Shareholders approved (i) pursuant to the Companies Act (As Revised) of the Cayman Islands, the redomestication of the Company from the Commonwealth of Massachusetts to the Cayman Islands by way of continuation and the resolutions of the Board of Directors approving the redomestication and (ii) as a special resolution for purposes of Cayman Islands law, the adoption of the memorandum and articles of association of the Company, substantially in the form attached as Annex B to the Proxy Statement (the “Continuation and Cayman Articles Proposal”). The voting results were as follows:
|
|
|
|
|
|
|
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
36,183,829 |
|
3,838,657 |
|
67 |
|
— |
Proposal No. 3. In connection with the Special Meeting, the Company also solicited proxies with respect to a proposal to adjourn the Special Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Redomestication Proposal. As there were sufficient votes to approve each of the Domestication Proposal and the Continuation and Cayman Articles Proposal, an adjournment of the Special Meeting was determined not to be necessary.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
KORSANA BIOSCIENCES, INC. |
|
|
|
|
Date: |
November 19, 2026 |
By: |
/s/ Mark Vignola |
|
|
|
Mark Vignola, Ph.D. Chief Financial Officer |